Archives

by in
Entry Author Date Location
Scientists Spot New Antibodies Against HIV, Opening Up Potential Path to AIDS Vaccine 08/17/11 National
Adventrx Shares Plummet, Pfizer Adds UC San Diego to its Network, New RNAi Center Opens, & More San Diego Life Sciences News 08/11/11 San Diego
Gilead HIV Drug Gets FDA OK 08/10/11 San Francisco
Gilead Buys Genentech Biologics Plant 08/08/11 San Diego
Bristol-Myers Acquires Amira Pharmaceuticals for $325 Million, Scoops Up Lung Drug 07/21/11 San Diego
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
Gilead Expands Low-Cost HIV Drug Program 07/12/11 San Francisco
Why Twitter Matters Now in Biotech, and Why Executives Can’t Ignore it Anymore 06/13/11 National
The Quest For Biotech Independence: Maybe It Isn’t So Quixotic After All 06/06/11 National
AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company 06/02/11 Seattle
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired 05/23/11 National
iPierian, Stem Cell Startup With Big Science & Big Bucks, Axes Group of Top Executives 05/13/11 San Francisco
Pharma-Academic Alliances: What the Numbers Don’t Tell You 05/10/11 Seattle
Gilead Cuts Deal With MicroDose 04/20/11 San Francisco
Gilead Drug Fails AIDS Prevention Trial 04/18/11 San Francisco
Gilead Antes Up for Cancer, Genentech Eye Drug Passes Big Trial, Bigger Isn’t Better, & More Bay Area Life Sciences News 04/01/11 San Francisco
Editor’s Picks: Xconomy Seattle’s Top Stories of the First Quarter 03/31/11 Seattle
Gilead Inks $100M Deal With Yale 03/31/11 San Francisco
Doxo, Kashless, Physiosonic led WA’s Equity Financing Deals in February 03/21/11 Seattle
Gilead Bets $600M on Cancer, Genentech Gets a Hearing, Jennerex Shows Early Survival Edge, & More Bay Area Life Sciences News 02/25/11 San Francisco
Gilead Wagers $600M on Calistoga, Dendreon Scopes New Digs, Physio to Spin Off, & More Seattle-Area Life Sciences News 02/24/11 Seattle
Gilead Pursues Cancer, Inflammation as Next Step To Diversify Beyond HIV 02/23/11 San Francisco
Calistoga Hands the Keys to Gilead, Bets It Can Make Cancer a Chronic Disease Like HIV 02/23/11 Seattle
Montgomery Startup Gets $1M 02/22/11 Seattle
Gilead Buys Calistoga Pharma for $375M, Making Move Into Cancer Drugs 02/22/11 Seattle
Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease 02/07/11 Boston
The State of Seattle Biotech 2011: Xconomy’s Chat With UW Faculty & Students 01/19/11 Seattle
See You at the JP Morgan Healthcare Conference 01/10/11 National
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science 01/06/11 Boston
Gilead Buys Arresto for $225M 12/20/10 San Francisco
Page 2 of 5 « previous page · next page »